KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Revenue (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Revenue data on record, last reported at $3.2 billion in Q4 2025.

  • For Q4 2025, Revenue rose 9.55% year-over-year to $3.2 billion; the TTM value through Dec 2025 reached $12.0 billion, up 8.9%, while the annual FY2025 figure was $12.0 billion, 8.9% up from the prior year.
  • Revenue reached $3.2 billion in Q4 2025 per VRTX's latest filing, up from $3.1 billion in the prior quarter.
  • Across five years, Revenue topped out at $3.2 billion in Q4 2025 and bottomed at $1.7 billion in Q1 2021.
  • Average Revenue over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2023.
  • Peak YoY movement for Revenue: increased 28.99% in 2021, then rose 2.96% in 2025.
  • A 5-year view of Revenue shows it stood at $2.1 billion in 2021, then rose by 11.1% to $2.3 billion in 2022, then increased by 9.34% to $2.5 billion in 2023, then rose by 15.66% to $2.9 billion in 2024, then rose by 9.55% to $3.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $3.2 billion in Q4 2025, $3.1 billion in Q3 2025, and $3.0 billion in Q2 2025.